Indication
for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer -in combination with fulvestrant in women who have received prior endocrine therapy

Medicine details

Medicine name:
palbociclib (Ibrance)
SMC ID:
SMC2180
Pharmaceutical company
Pfizer Ltd
BNF chapter
Submission type
Full
Status
Publication due date:
08 July 2019
SMC meeting date:
04 June 2019
Patient group submission deadline:
01 April 2019